| Abecma |
125736 |
001 |
351(a) |
idecabtagene vicleucel |
Suspension |
Intravenous |
300 to 460 X 10^6 CHIMERIC ANTIGEN RECEPTOR (CAR)-POSITIVE T CELLS |
Bag |
2021/03/03
|
Celgene Corporation, a Bristol-Myers Squibb Company |
Rx |
Licensed |
N/A |
N/A |
| Evkeeza |
761181 |
001 |
351(a) |
evinacumab-dgnb |
Injection |
Intravenous |
345MG/2.3ML (150MG/ML) |
Single-Dose Vial |
2021/02/11
|
Regeneron Pharmaceuticals, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Evkeeza |
761181 |
002 |
351(a) |
evinacumab-dgnb |
Injection |
Intravenous |
1,200MG/8ML (150MG/ML) |
Single-Dose Vial |
2021/02/11
|
Regeneron Pharmaceuticals, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Breyanzi |
125714 |
001 |
351(a) |
lisocabtagene maraleucel |
Injection |
Intravenous |
4.6ML/VIAL |
Single-Dose Vial |
2021/02/05
|
Juno Therapeutics, Inc. a Bristol Myer-Squibb Company |
Rx |
Licensed |
|
|
| Vaxchora |
125597 |
002 |
351(a) |
Cholera Vaccine, Live, Oral |
Suspension |
Oral |
50ML |
Packet |
2020/12/23
|
Bavarian Nordic A/S |
Rx |
Licensed |
N/A |
N/A |
| Vaxchora |
125597 |
003 |
351(a) |
Cholera Vaccine, Live, Oral |
Suspension |
Oral |
100ML |
Packet |
2020/12/23
|
Bavarian Nordic A/S |
Rx |
Licensed |
N/A |
N/A |
| Ebanga |
761172 |
001 |
351(a) |
ansuvimab-zykl |
For Injection |
Intravenous |
400MG |
Single-Dose Vial |
2020/12/21
|
Emergent Manufacturing Operations Baltimore LLC |
Rx |
Licensed |
N/A |
N/A |
| Riabni |
761140 |
001 |
351(k) Biosimilar |
rituximab-arrx |
Injection |
Intravenous |
100MG/10ML (10MG/ML) |
Single-Dose Vial |
2020/12/17
|
Amgen Inc. |
Rx |
Licensed |
rituximab |
Rituxan |
| Riabni |
761140 |
002 |
351(k) Biosimilar |
rituximab-arrx |
Injection |
Intravenous |
500MG/50ML (10MG/ML) |
Single-Dose Vial |
2020/12/17
|
Amgen Inc. |
Rx |
Licensed |
rituximab |
Rituxan |
| Margenza |
761150 |
001 |
351(a) |
margetuximab-cmkb |
Injection |
Intravenous |
250MG/10ML (25MG/ML) |
Single-Dose Vial |
2020/12/16
|
MacroGenics Inc. |
Rx |
Licensed |
N/A |
N/A |
| Trazimera |
761081 |
002 |
351(k) Biosimilar |
trastuzumab-qyyp |
For Injection |
Intravenous |
150MG |
Multi-Dose Vial |
2020/11/30
|
Pfizer Ireland Pharmaceuticals |
Rx |
Licensed |
trastuzumab |
Herceptin |
| Danyelza |
761171 |
001 |
351(a) |
naxitamab-gqgk |
Injection |
Intravenous |
40MG/10ML (4MG/ML) |
Single-Dose Vial |
2020/11/25
|
Y-mABs Therapeutics, Inc |
Rx |
Licensed |
N/A |
N/A |
| Inmazeb |
761169 |
001 |
351(a) |
atoltivimab, maftivimab, and odesivimab-ebgn |
Injection |
Intravenous |
241.7MG, 241.7MG, 241.7MG/14.5ML (16.67MG, 16.67MG, 16.67MG/ML) |
Single-Dose Vial |
2020/10/14
|
Regeneron Pharmaceuticals, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Ultomiris |
761108 |
002 |
351(a) |
ravulizumab-cwvz |
Injection |
Intravenous |
300MG/3ML (100MG/ML) |
Single-Dose Vial |
2020/10/09
|
Alexion Pharmaceuticals, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Ultomiris |
761108 |
003 |
351(a) |
ravulizumab-cwvz |
Injection |
Intravenous |
1,100MG/11ML (100MG/ML) |
Single-Dose Vial |
2020/10/09
|
Alexion Pharmaceuticals, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Vaxelis |
125563 |
002 |
351(a) |
Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine |
Injection |
Intramuscular |
0.5ML |
Pre-Filled Syringe |
2020/09/25
|
MSP Vaccine Company |
Rx |
Licensed |
|
N/A |
| Polivy |
761121 |
002 |
351(a) |
polatuzumab vedotin-piiq |
For Injection |
Intravenous |
30MG |
Single-Dose Vial |
2020/09/18
|
Genentech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Trulicity |
125469 |
005 |
351(a) |
dulaglutide |
Injection |
Subcutaneous |
3MG/0.5ML |
Autoinjector |
2020/09/04
|
Eli Lilly and Company |
Rx |
Licensed |
N/A |
N/A |
| Trulicity |
125469 |
006 |
351(a) |
dulaglutide |
Injection |
Subcutaneous |
4.5MG/0.5ML |
Autoinjector |
2020/09/04
|
Eli Lilly and Company |
Rx |
Licensed |
N/A |
N/A |
| Sogroya |
761156 |
001 |
351(a) |
somapacitan-beco |
Injection |
Subcutaneous |
10MG/1.5ML (6.7MG/ML) |
Autoinjector |
2020/08/28
|
Novo Nordisk Inc. |
Rx |
Licensed |
N/A |
N/A |